JP5005162B2 - ベナゼプリル及びその類似体の生産に有用な中間体の速度論的分離 - Google Patents
ベナゼプリル及びその類似体の生産に有用な中間体の速度論的分離 Download PDFInfo
- Publication number
- JP5005162B2 JP5005162B2 JP2003509986A JP2003509986A JP5005162B2 JP 5005162 B2 JP5005162 B2 JP 5005162B2 JP 2003509986 A JP2003509986 A JP 2003509986A JP 2003509986 A JP2003509986 A JP 2003509986A JP 5005162 B2 JP5005162 B2 JP 5005162B2
- Authority
- JP
- Japan
- Prior art keywords
- halide
- compound
- reaction
- benazepril
- carbonate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- XPCFTKFZXHTYIP-PMACEKPBSA-N Benazepril Chemical compound C([C@@H](C(=O)OCC)N[C@@H]1C(N(CC(O)=O)C2=CC=CC=C2CC1)=O)CC1=CC=CC=C1 XPCFTKFZXHTYIP-PMACEKPBSA-N 0.000 title abstract description 10
- 229960004530 benazepril Drugs 0.000 title abstract description 10
- 238000000926 separation method Methods 0.000 title description 9
- 238000004519 manufacturing process Methods 0.000 title description 6
- 238000000034 method Methods 0.000 claims abstract description 40
- 150000001875 compounds Chemical class 0.000 claims abstract description 24
- 238000006243 chemical reaction Methods 0.000 claims description 15
- -1 tetra-alkylammonium halide Chemical class 0.000 claims description 14
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical group [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 claims description 8
- 125000000217 alkyl group Chemical group 0.000 claims description 7
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 6
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims description 6
- 229910052736 halogen Inorganic materials 0.000 claims description 5
- 150000002367 halogens Chemical class 0.000 claims description 5
- 229910052739 hydrogen Inorganic materials 0.000 claims description 4
- 239000001257 hydrogen Substances 0.000 claims description 4
- 239000002798 polar solvent Substances 0.000 claims description 4
- 239000003444 phase transfer catalyst Substances 0.000 claims description 3
- 229910000027 potassium carbonate Inorganic materials 0.000 claims description 3
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 3
- 235000009518 sodium iodide Nutrition 0.000 claims description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 2
- VPSRQEHTHIMDQM-FKLPMGAJSA-N benazepril hydrochloride Chemical compound Cl.C([C@@H](C(=O)OCC)N[C@@H]1C(N(CC(O)=O)C2=CC=CC=C2CC1)=O)CC1=CC=CC=C1 VPSRQEHTHIMDQM-FKLPMGAJSA-N 0.000 claims description 2
- 229960003619 benazepril hydrochloride Drugs 0.000 claims description 2
- 125000004432 carbon atom Chemical group C* 0.000 claims description 2
- 150000002431 hydrogen Chemical class 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- AYJRCSIUFZENHW-UHFFFAOYSA-L barium carbonate Chemical compound [Ba+2].[O-]C([O-])=O AYJRCSIUFZENHW-UHFFFAOYSA-L 0.000 claims 2
- 150000004820 halides Chemical class 0.000 claims 2
- HSZCZNFXUDYRKD-UHFFFAOYSA-M lithium iodide Chemical compound [Li+].[I-] HSZCZNFXUDYRKD-UHFFFAOYSA-M 0.000 claims 2
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 claims 1
- 229910052783 alkali metal Inorganic materials 0.000 claims 1
- 239000002585 base Substances 0.000 claims 1
- 229960003872 benzethonium Drugs 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- XGZVUEUWXADBQD-UHFFFAOYSA-L lithium carbonate Chemical compound [Li+].[Li+].[O-]C([O-])=O XGZVUEUWXADBQD-UHFFFAOYSA-L 0.000 claims 1
- 229910052808 lithium carbonate Inorganic materials 0.000 claims 1
- FVPMMSKYNHPFOI-UHFFFAOYSA-M methyl sulfate;trimethyl(phenyl)azanium Chemical compound COS([O-])(=O)=O.C[N+](C)(C)C1=CC=CC=C1 FVPMMSKYNHPFOI-UHFFFAOYSA-M 0.000 claims 1
- 229910000028 potassium bicarbonate Inorganic materials 0.000 claims 1
- 235000015497 potassium bicarbonate Nutrition 0.000 claims 1
- 239000011736 potassium bicarbonate Substances 0.000 claims 1
- 235000011181 potassium carbonates Nutrition 0.000 claims 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 claims 1
- 235000017550 sodium carbonate Nutrition 0.000 claims 1
- 238000006345 epimerization reaction Methods 0.000 abstract description 18
- 229910052717 sulfur Inorganic materials 0.000 description 36
- 239000000203 mixture Substances 0.000 description 21
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 18
- 238000004128 high performance liquid chromatography Methods 0.000 description 15
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 14
- 239000007787 solid Substances 0.000 description 9
- 238000001914 filtration Methods 0.000 description 8
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 7
- 239000011541 reaction mixture Substances 0.000 description 7
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical group Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 238000002425 crystallisation Methods 0.000 description 6
- 239000002002 slurry Substances 0.000 description 6
- FKLJPTJMIBLJAV-UHFFFAOYSA-N Compound IV Chemical compound O1N=C(C)C=C1CCCCCCCOC1=CC=C(C=2OCCN=2)C=C1 FKLJPTJMIBLJAV-UHFFFAOYSA-N 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 230000008025 crystallization Effects 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 4
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 125000003277 amino group Chemical group 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 4
- 239000000543 intermediate Substances 0.000 description 4
- 230000006340 racemization Effects 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 239000008096 xylene Substances 0.000 description 4
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 150000003951 lactams Chemical class 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- HRVRAYIYXRVAPR-UHFFFAOYSA-N 1,3,4,5-tetrahydro-1-benzazepin-2-one Chemical class N1C(=O)CCCC2=CC=CC=C21 HRVRAYIYXRVAPR-UHFFFAOYSA-N 0.000 description 2
- UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 description 2
- JMXPGCGROVEPID-UHFFFAOYSA-N 3-bromo-1,3,4,5-tetrahydro-1-benzazepin-2-one Chemical compound N1C(=O)C(Br)CCC2=CC=CC=C21 JMXPGCGROVEPID-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- JTTHKOPSMAVJFE-VIFPVBQESA-N L-homophenylalanine Chemical group OC(=O)[C@@H](N)CCC1=CC=CC=C1 JTTHKOPSMAVJFE-VIFPVBQESA-N 0.000 description 2
- 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 description 2
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- RDHPKYGYEGBMSE-UHFFFAOYSA-N bromoethane Chemical compound CCBr RDHPKYGYEGBMSE-UHFFFAOYSA-N 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000032050 esterification Effects 0.000 description 2
- 238000005886 esterification reaction Methods 0.000 description 2
- 125000004494 ethyl ester group Chemical group 0.000 description 2
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 2
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 2
- NKZNPRQIONEKPT-UHFFFAOYSA-N n,n-dimethyl-1-quinolin-2-ylmethanamine Chemical compound C1=CC=CC2=NC(CN(C)C)=CC=C21 NKZNPRQIONEKPT-UHFFFAOYSA-N 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 239000012454 non-polar solvent Substances 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 235000019260 propionic acid Nutrition 0.000 description 2
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 2
- 238000004064 recycling Methods 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- JRMUNVKIHCOMHV-UHFFFAOYSA-M tetrabutylammonium bromide Chemical compound [Br-].CCCC[N+](CCCC)(CCCC)CCCC JRMUNVKIHCOMHV-UHFFFAOYSA-M 0.000 description 2
- VTQGYRVGBASLDF-YFKPBYRVSA-N (4s)-4-aminoazepan-2-one Chemical compound N[C@H]1CCCNC(=O)C1 VTQGYRVGBASLDF-YFKPBYRVSA-N 0.000 description 1
- 0 **[C@](*)CCc1ccccc1 Chemical compound **[C@](*)CCc1ccccc1 0.000 description 1
- FJZLANUAMGHEGO-UHFFFAOYSA-N 1,3-dihydro-1-benzazepin-2-one Chemical compound N1C(=O)CC=CC2=CC=CC=C21 FJZLANUAMGHEGO-UHFFFAOYSA-N 0.000 description 1
- 239000005541 ACE inhibitor Substances 0.000 description 1
- 206010007558 Cardiac failure chronic Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 1
- 229910001508 alkali metal halide Inorganic materials 0.000 description 1
- 150000008045 alkali metal halides Chemical class 0.000 description 1
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical class OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 208000022831 chronic renal failure syndrome Diseases 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- AEDZKIACDBYJLQ-UHFFFAOYSA-N ethane-1,2-diol;hydrate Chemical compound O.OCCO AEDZKIACDBYJLQ-UHFFFAOYSA-N 0.000 description 1
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- WFKAJVHLWXSISD-UHFFFAOYSA-N isobutyramide Chemical compound CC(C)C(N)=O WFKAJVHLWXSISD-UHFFFAOYSA-N 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 150000003871 sulfonates Chemical class 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000007039 two-step reaction Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D223/16—Benzazepines; Hydrogenated benzazepines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Health & Medical Sciences (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Description
ヨウ化ナトリウム(0.96g)を加えて、ハロゲンの交換の反応速度を促進し、副産物の量を減少することを除いて、実施例Aの方法を繰り返した。その結果は、40.7%の(1’S,3S)−3−[(1’−(エトキシカルボニル)−3’−フェニルプロピル)アミノ]−2,3,4,5−テトラヒドロ−2−オキソ−1H−ベンザゼピンと、41.4%の(1’S,3R)−3−[(1’−(エトキシカルボニル)−3’−フェニルプロピル)アミノ]−2,3,4,5−テトラヒドロ−2−オキソ−1H−ベンザゼピンを含む混合物を示した。
(1’S,3R,S)−3−[(1’−カルボキシル−3’−フェニルプロピル)アミノ]−2,3,4,5−テトラヒドロ−2−オキソ−1H−ベンザゼピン(IV)
(1’S,3R,S)−3−[(1’−カルボキシル−3’−フェニルプロピル)アミノ]−2,3,4,5−テトラヒドロ−2−オキソ−1H−ベンザピンエチルエステル(III)(2.47kg)を、1リットルのメタノールに溶解した。その後、3N水性NaOH(2.4L)を反応混合物に加え、混合物を40−50℃で2時間攪拌した。スラリーを冷却し、2N塩化水素酸(3436ml)を加えて溶液を酸性化した。蒸留によりメタノールを除去して固体を生産し、それを濾過し、水で洗浄し、減圧下で乾燥し、1.86kgの粗酸(IV)を得た。
(1’S,3,S)−3−[(1’−カルボキシル−3’−フェニルプロピル)アミノ]−2,3,4,5−テトラヒドロ−2−オキソ−1H−ベンザゼピン(V)
キシレン(30L)を1.86kgの化合物IVに加えた。スラリーを、約1.5気圧で150−155℃で8時間加熱した。反応混合物を室温に冷却した。固体を濾過によって回収し、減圧下で乾燥し、HPLCによって測定すると98:2のS,S:R,Sジアステレオマー混合物として、1.67kgの(S,S)ジアステレオマー(V)を得た。HPLCによって測定するとエナンチオマーの比は、S,S:R,R=93:7であり、化学収率は92%であった。前記化合物は以下の特徴を有した:
実施例4と同様な態様で、キシレン(2.76L)を化合物IV(83g)に加えた。スラリーを138−143℃に加熱し、この温度で3時間維持した。この期間の後、混合物を室温に冷却した。濾過により固体を回収し、減圧下で乾燥し、HPLCにより測定すると97:03のジアステレオマー混合物として、74.7gの化合物V(S,S)を得た。HPLCにより測定するとエナンチオマーの比は、SS:RR=95:05であり、収率は86%である。
実施例4と同様な態様で、プロピオン酸(12ml)を化合物IV(2g)に加えた。スラリーを60℃で30分攪拌した。この期間の後、反応混合物を25℃に冷却した。濾過により固体を回収し、酢酸エチルで洗浄し、減圧下で乾燥し、HPLCにより測定すると70:30のジアステレオマー混合物として、1.5gの化合物Vを得た。HPLCにより測定するとエナンチオマーの比は、SS:RR=86:14であり、収率は75%である。
実施例4と同様な態様で、酢酸(6ml)を化合物IV(1g)に加えた。スラリーを室温で1時間攪拌した。濾過により固体を回収し、酢酸エチルで洗浄し、減圧下で乾燥し、HPLCにより測定すると99:1のジアステレオマー混合物として、0.7gの化合物Vを得た。HPLCにより測定するとエナンチオマーの比は、SS:RR=85:15であり、収率は70%である。
実施例4と同様な態様で、エチレングリコール(9ml)とH2O(1ml)を化合物IV(1g)に加えた。スラリーを138℃に加熱し、この温度で3.5時間攪拌した。この期間の後、反応混合物を25℃に冷却した。濾過により固体を回収し、酢酸エチルで洗浄し、減圧下で乾燥し、HPLCにより測定すると99:01のジアステレオマー混合物として、0.83gの化合物Vを得た。HPLCにより測定するとエナンチオマーの比は、SS:RR=81:19であり、収率は83%である。
(1’S,3R)−3−[(1’−カルボキシル−3’−フェニルプロピル)アミノ]−2,3,4,5−テトラヒドロ−2−オキソ−1H−ベンザゼピン(100mg)とTHF(5mL)を混合し、0℃に冷却した。次いでCH3ONa(30mg)を反応混合物に加えた。次いで反応温度を25℃で1時間維持した。3N HCl溶液によってpHを2.5から2.0に調節した。固体を濾過により回収し、減圧下で乾燥し、HPLCにより測定すると54:46のS,S:R,Sのジアステレオマー混合物として、93mgの化合物(IV)を得た。
(1’S,3S)−3−[(1’−(エトキシカルボニル)−3’−フェニルプロピル)アミノ]−2,3,4,5−テトラヒドロ−2−オキソ−1H−ベンザゼピン(VI)
化合物V(450g)、N,N−ジメチルアセチルアミド(2L)、ブロモエタン(115ml)、及び炭酸カリウム(65g)を、反応フラスコに加えた。反応混合物を60−70℃に加熱し、この温度で2時間攪拌した。混合物を冷却し、3.5Lの水を10℃で混合物に加えた。生成した沈降物を濾過により回収し、さらに2Lの水で洗浄し、減圧下で乾燥し、520gの粗固体を得た。この固体を、0.6Lの酢酸エチルと1.2Lのヘプタンの混合物に40−50℃で溶解した。溶液を30℃に冷却し、生産物を濾過により単離し、HPLCにより測定すると>99:1のジアステレオマー混合物として390gのVI(S,S)を得た。HPLCにより測定したエナンチオマーの比は、SS:RRが>99.5:0.5であり、収率は80%である。この化合物は以下のような特徴を有する:
Claims (8)
- 相間移動触媒が、テトラ−アルキルアンモニウムハライド、N−ドデシル−N−メチル−エフェドリニウムハライド、フェニルトリメチルアンモニウムハライド、フェニルトリメチルアンモニウムメトスルファート、ベンジルトリメチルアンモニウムハライド、N−ベンジルシンコニニウムハライド、ベンジルジメチルドデシルアンモニウムハライド、及びベンゼトニウムハライドからなる群から選択される、請求項1に記載の方法。
- 前記反応が、アルカリ金属ハライド塩によってさらに触媒される、請求項1に記載の方法。
- 前記塩が、ヨウ化ナトリウムまたはヨウ化リチウムである、請求項3に記載の方法。
- 前記反応が、塩基性条件下で実施される、請求項1に記載の方法。
- 前記塩基性条件が、重炭酸ナトリウム、炭酸ナトリウム、重炭酸カリウム、炭酸カリウム、炭酸リチウム、及び炭酸バリウムからなる群から選択される塩基を添加することによって提供される、請求項5に記載の方法。
- 前記反応温度が60℃から140℃の間である、請求項1に記載の方法。
- 式(III)の化合物が塩酸ベナゼプリルに更に変換される、請求項1に記載の方法。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US29188801P | 2001-05-18 | 2001-05-18 | |
US60/291,888 | 2001-05-18 | ||
US09/910,509 | 2001-07-19 | ||
US09/910,509 US6548665B2 (en) | 2001-05-18 | 2001-07-19 | Asymmetric synthesis of a key intermediate for making benazepril and analogues thereof |
PCT/IB2002/003060 WO2003003972A2 (en) | 2001-05-18 | 2002-05-20 | Kinetic resolution of a intermediate useful in the production of benazepril and analogues thereof |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2009032656A Division JP5254836B2 (ja) | 2001-05-18 | 2009-02-16 | ベナゼプリル及びその類似体の生産に有用な中間体の速度論的分離 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2005501028A JP2005501028A (ja) | 2005-01-13 |
JP2005501028A5 JP2005501028A5 (ja) | 2005-07-21 |
JP5005162B2 true JP5005162B2 (ja) | 2012-08-22 |
Family
ID=26967030
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2003509986A Expired - Fee Related JP5005162B2 (ja) | 2001-05-18 | 2002-05-20 | ベナゼプリル及びその類似体の生産に有用な中間体の速度論的分離 |
JP2009032656A Expired - Fee Related JP5254836B2 (ja) | 2001-05-18 | 2009-02-16 | ベナゼプリル及びその類似体の生産に有用な中間体の速度論的分離 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2009032656A Expired - Fee Related JP5254836B2 (ja) | 2001-05-18 | 2009-02-16 | ベナゼプリル及びその類似体の生産に有用な中間体の速度論的分離 |
Country Status (11)
Country | Link |
---|---|
US (2) | US6548665B2 (ja) |
EP (1) | EP1430031B1 (ja) |
JP (2) | JP5005162B2 (ja) |
CN (1) | CN1266136C (ja) |
AT (1) | ATE416169T1 (ja) |
AU (1) | AU2002354753B2 (ja) |
CA (1) | CA2455526C (ja) |
DE (1) | DE60230166D1 (ja) |
ES (1) | ES2316591T3 (ja) |
NZ (1) | NZ530111A (ja) |
WO (1) | WO2003003972A2 (ja) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1730326A4 (en) * | 2004-01-16 | 2008-05-28 | Battelle Memorial Institute | METHOD AND DEVICE FOR PREPARING FERRATE (VI) |
US8034253B2 (en) * | 2004-11-12 | 2011-10-11 | Battelle Memorial Insitute | Decontaminant |
WO2008080822A1 (en) * | 2006-12-29 | 2008-07-10 | F. Hoffmann-La Roche Ag | Epimerization methodologies for recovering stereo isomers in high yield and purity |
WO2008112657A1 (en) | 2007-03-09 | 2008-09-18 | Battelle Memorial Institute | Ferrate(vi)-containing compositions and methods of using ferrate(vi) |
EP2268345A1 (en) * | 2008-03-26 | 2011-01-05 | Battelle Memorial Institute | Apparatus and methods of providing diatomic oxygen (o2) using ferrate(vi)-containing compositions |
US8722147B2 (en) * | 2008-10-17 | 2014-05-13 | Battelle Memorial Institute | Corrosion resistant primer coating |
CN101830850B (zh) * | 2009-12-29 | 2013-07-10 | 海门慧聚药业有限公司 | (1's)-高苯丙氨酸羧酸酯-苯并氮杂卓-双手性化合物的高效制备方法 |
WO2023181054A1 (en) * | 2022-03-19 | 2023-09-28 | Aarti Industries Limited | Improved process for synthesis of benazepril intermediate |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4410520A (en) * | 1981-11-09 | 1983-10-18 | Ciba-Geigy Corporation | 3-Amino-[1]-benzazepin-2-one-1-alkanoic acids |
JPH11322684A (ja) * | 1998-05-12 | 1999-11-24 | Yamakawa Yakuhin Kogyo Kk | アミノ酸類の異性化方法 |
-
2001
- 2001-07-19 US US09/910,509 patent/US6548665B2/en not_active Expired - Lifetime
-
2002
- 2002-05-20 DE DE60230166T patent/DE60230166D1/de not_active Expired - Lifetime
- 2002-05-20 CA CA2455526A patent/CA2455526C/en not_active Expired - Fee Related
- 2002-05-20 EP EP02751512A patent/EP1430031B1/en not_active Expired - Lifetime
- 2002-05-20 NZ NZ530111A patent/NZ530111A/xx not_active IP Right Cessation
- 2002-05-20 AT AT02751512T patent/ATE416169T1/de not_active IP Right Cessation
- 2002-05-20 JP JP2003509986A patent/JP5005162B2/ja not_active Expired - Fee Related
- 2002-05-20 ES ES02751512T patent/ES2316591T3/es not_active Expired - Lifetime
- 2002-05-20 WO PCT/IB2002/003060 patent/WO2003003972A2/en active Search and Examination
- 2002-05-20 CN CNB028101375A patent/CN1266136C/zh not_active Expired - Fee Related
- 2002-05-20 AU AU2002354753A patent/AU2002354753B2/en not_active Ceased
- 2002-05-21 US US10/151,772 patent/US20030055245A1/en not_active Abandoned
-
2009
- 2009-02-16 JP JP2009032656A patent/JP5254836B2/ja not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
EP1430031A4 (en) | 2004-10-13 |
DE60230166D1 (de) | 2009-01-15 |
CA2455526C (en) | 2010-10-12 |
CN1537103A (zh) | 2004-10-13 |
JP5254836B2 (ja) | 2013-08-07 |
ATE416169T1 (de) | 2008-12-15 |
US20020183515A1 (en) | 2002-12-05 |
EP1430031B1 (en) | 2008-12-03 |
NZ530111A (en) | 2006-03-31 |
ES2316591T3 (es) | 2009-04-16 |
JP2005501028A (ja) | 2005-01-13 |
JP2009102441A (ja) | 2009-05-14 |
US6548665B2 (en) | 2003-04-15 |
US20030055245A1 (en) | 2003-03-20 |
WO2003003972A2 (en) | 2003-01-16 |
EP1430031A2 (en) | 2004-06-23 |
CA2455526A1 (en) | 2003-01-16 |
WO2003003972A3 (en) | 2004-04-29 |
CN1266136C (zh) | 2006-07-26 |
AU2002354753B2 (en) | 2008-08-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5254836B2 (ja) | ベナゼプリル及びその類似体の生産に有用な中間体の速度論的分離 | |
JP5203703B2 (ja) | イルベサルタンおよびその中間体の製造方法 | |
JP3224271B2 (ja) | 鏡像異性的に純粋な置換された(キノリン−2−イル−メトキシ)−フエニル酢酸の合成方法 | |
JP2002265444A (ja) | 1−(3−ベンジルオキシプロピル)−5−(2−置換プロピル)インドリン誘導体およびその使用方法 | |
US20120041044A1 (en) | Process for the preparation of carvedilol and its enantiomers | |
JP2011503122A (ja) | 4,5−ジメトキシ−1−(メチルアミノメチル)−ベンゾシクロブタンの分離 | |
JP5899204B2 (ja) | キラルなβ−アミノカルボキサミド誘導体の製造方法 | |
AU2002354753A1 (en) | Kinetic resolution of a intermediate useful in the production of benazepril and analogues thereof | |
KR20020005648A (ko) | 삼환성 아미노알콜 유도체의 아지드를 경유하는 제조법 | |
US8431717B2 (en) | Process for the preparation of 5-(2-ethyl-dihydro-1H-inden-2-yl)-1H-imidazole and salts thereof | |
JP2003534241A (ja) | N−〔(s)−1−カルボキシブチル〕−(s)−アラニンエステルの新規合成方法及びペリンドプリルの合成における適用 | |
JPH1087633A (ja) | キラルなコハク酸誘導体の製造方法 | |
JP4126921B2 (ja) | 光学活性なβ−フェニルアラニン誘導体の製造方法 | |
JP2008115179A (ja) | 光学活性2−[(n−ベンジルプロリル)アミノ]ベンゾフェノン化合物の製造方法 | |
JP3867433B2 (ja) | 1,1’−ビナフチル−2,2’−ジカルボン酸の光学分割方法 | |
EP0990637A1 (en) | Process for producing ketoprofen and 5-benzoyl-3-methyl-2-indolinone | |
WO2001017944A1 (fr) | Procede relatif a l'elaboration d'aminoalcool optiquement actif | |
WO2001079176A1 (en) | Process for preparation of 3-[(1'-(alkoxycarbonyl)-3'-phenylpropyl)amino]-2-oxo-[1]-benzazepine and its derivatives | |
JPH09104663A (ja) | 光学活性 1−(m−ベンジルオキシフェニル) アルキルアミン類の製造方法 | |
JP2003137885A (ja) | 光学活性4−[(オキシラン−2−イルメチル)オキシ]−1h−インドールの精製、単離方法 | |
JPH10195015A (ja) | 2−ベンジルコハク酸化合物の光学分割方法 | |
JP2000080062A (ja) | 光学活性1―アリ―ルアルキルアミン類の製造方法およびその中間体 | |
JP2004503539A (ja) | 望ましくない鏡像体のinsitu同時ラセミ化を伴うピペリドン誘導体の鏡像体の分離 | |
JP2002138086A (ja) | アルキルオキシアミノフラノン誘導体の製造方法 | |
KR20090053058A (ko) | 신규 광학 분할제 및 이를 이용하여 광학 이성질체를분리하는 방법 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20050308 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20081021 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20090116 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20090123 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090216 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20090317 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120329 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20120523 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20150601 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
LAPS | Cancellation because of no payment of annual fees |